Initial experience using middle meningeal artery embolisation for patients with recurrent and high-recurrence-risk chronic subdural haematoma.

CSDH Embolisation Haematoma MMAe Meningeal Subdural

Journal

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
ISSN: 1532-2653
Titre abrégé: J Clin Neurosci
Pays: Scotland
ID NLM: 9433352

Informations de publication

Date de publication:
23 May 2024
Historique:
received: 29 01 2024
revised: 02 05 2024
accepted: 19 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 24 5 2024
Statut: aheadofprint

Résumé

Recurrence rates following surgical management of chronic subdural haematoma (CSDH) range from 5 to 33 %. There is growing evidence which suggests middle meningeal artery embolisation (MMAe) may reduce recurrence rates when used as surgical adjunct or standalone treatment. In this study we described our experience of this new procedure in the our UK institution. Patients with recurrent CSDH or CSDH at high risk of recurrence were selected for MMAe on a case-by-case basis following MDT discussion. A departmental database was used to identify patients treated. 26 CSDH were embolised in 20 patients; 9 CSDH were de-novo and 17 were recurrent. 10/26 CSDH were treated with MMAe only. No procedural mortality, access site or thrombo-embolic complications occurred. One patient experienced symptomatic collection growth 12 h following MMAe and required surgical drainage. 15 (75 %) of patients were living at home at follow-up (mean 14 months). On imaging follow-up 15/18 showed CSDH volume reduction or resolution, 1/18 remained stable requiring no further treatment, 2/18 patients suffered recurrent CSDH requiring treatment. In both recurrent cases incomplete embolisation was noted on procedural imaging (posterior division of MMA not embolised). Persistent posterior MMA division filling was significantly associated with collection recurrence (p = 0.002). Our results suggest MMAe as a stand-alone or adjuvant therapy can be performed safely in a UK neuroscience setting and is associated with high rates of symptomatic CSDH size reduction or resolution in problematic CSDH that have either recurred or are prone to recurrence.

Identifiants

pubmed: 38788605
pii: S0967-5868(24)00210-8
doi: 10.1016/j.jocn.2024.05.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

126-131

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

R Flood (R)

Southmead Hospital, North Bristol NHS Trust, United Kingdom. Electronic address: Richard.flood@nbt.nhs.uk.

A C Nunn (AC)

Southmead Hospital, North Bristol NHS Trust, United Kingdom.

J Talbott (J)

Blackpool Victoria Hospital, Blackpool Teaching Hospital NHS Foundation Trust, United Kingdom.

A Cox (A)

Southmead Hospital, North Bristol NHS Trust, United Kingdom.

D Minks (D)

Southmead Hospital, North Bristol NHS Trust, United Kingdom.

J Wareham (J)

Southmead Hospital, North Bristol NHS Trust, United Kingdom.

R Crossley (R)

Southmead Hospital, North Bristol NHS Trust, United Kingdom.

G Malcolm (G)

Southmead Hospital, North Bristol NHS Trust, United Kingdom.

N K Patel (NK)

Southmead Hospital, North Bristol NHS Trust, United Kingdom.

C Wigfield (C)

Southmead Hospital, North Bristol NHS Trust, United Kingdom.

A Williams (A)

Southmead Hospital, North Bristol NHS Trust, United Kingdom.

A Mortimer (A)

Southmead Hospital, North Bristol NHS Trust, United Kingdom.

Classifications MeSH